| Similar Articles |
|---|
 |
Bio-IT World
September 16, 2004
Zachary Zimmerman |
The Dark Side of Project BioShield Despite the uncertainties, an estimated 100 biopharma companies are developing anti-terror technologies. But they should examine both sides of Project BioShield before considering product development.   |
Pharmaceutical Executive
May 1, 2005
L.J. Sellers |
It's All About Immunity Hollis-Eden is developing drugs that help the body fight foreign attackers -- including radiation. Other companies are in competition to bring new autoimmune drugs to the market, but Hollis-Eden believes its compounds will be significantly more effective |
National Defense
June 2007
Breanne Wagner |
Agencies Scramble to Create Vaccine Market Defense and Homeland Security are pursuing disparate vaccination programs to combat different needs for military and civilian populations. |
National Defense
November 2005
Margaret Davidson |
Biodefense Experts: Vaccines `At a Crossroads' Many of the companies seeking government funds for biodefense work are small firms with no experience in bringing a drug to market. And they face a significant challenge. |
The Motley Fool
December 21, 2004
Charly Travers |
Invest With Fewer Side Effects Averse to risk? Check out these nontraditional drug companies: Biogen Idec... Elan... Salix Pharmaceuticals... Atrix Laboratories... etc. |
The Motley Fool
November 16, 2004
Charly Travers |
Finding Biotech's 50-Baggers Finding these superb biotechs isn't a search for a once-in-a-lifetime opportunity. These great investments pop up a lot more frequently than you may think. |
National Defense
July 2009 |
Readers Sound Off on Recent Stories 7 Deadly Myth article draws comment. |
The Motley Fool
May 31, 2006
Stephen D. Simpson |
Vical Gets a Helping Hand Japan's AnGes MG's Allovectin-7 vaccine is now a risk-free lottery ticket for Vical. If phase 3 trials show adequate efficacy, there's upside. If the trials fail, Vical really doesn't lose much of anything. Investors, take note. |
The Motley Fool
April 29, 2005
Charly Travers |
Value in Drug Stocks? Looking at some big pharma companies and liking what you see? Take a peek at biotech, too. GlaxoSmithKline... Pfizer... Amgen... Genzyme... etc. |
Wired
September 2002
Amanda Griscom |
Take These Genes and Call Me in the Morning Gene vaccines may be relatively new, but they're the logical outgrowth of two familiar strands of medical science. |
Pharmaceutical Executive
July 3, 2007
Jill Wechsler |
Washington Report: Vaccines for Everyone New vaccines can be good business and a huge boon to public health. But the challenge is to establish prices that ensure global access, and to bring necessary medications to third-world countries. |
The Motley Fool
September 9, 2004
Charly Travers |
The Case for Drug Stocks The reports of the drug industry's death are greatly exaggerated. |
National Defense
June 2011
Eric Beidel |
Industry, Academia Race to Create Drugs Against Biological Warfare On the heels of anthrax comes a string of deadly agents that scientists also fear can be used as weapons and spread with ease. |
Wired
January 2003
Richard Martin |
Testing the First AIDS Vaccine Medical establishment, government, and Genentech be damned -- Don Francis has never stopped believing. Now he's about to finish testing the first human AIDS vaccine. |
BusinessWeek
October 24, 2005
John Carey |
New Vaccines For A Pandemic Using DNA, vast amounts of flu vaccine could be made quickly. But will the drugs work? |
The Motley Fool
September 24, 2009
Brian Orelli |
Drugmakers' HIV Treatments Live On Companies that make HIV drugs could lose billions of dollars in revenue if an effective vaccine is developed. All drug-company investors need to keep an eye on up-and-coming drugs from competitors that could take market share. |
Popular Mechanics
October 22, 2008
Kate Schweitzer |
On Fringe, Radioactivity is Real, But Cures are Junk Science Radiation experts give their opinion on the mad science of this television show. |
Pharmaceutical Executive
October 1, 2014
Jill Wechsler |
Ebola Crisis Challenges Pharma R&D Companies gain support and pressure to deliver new treatments for spreading outbreak. |
Salon.com
October 9, 2001
Suzy Hansen |
Plague fears A bioterrorism expert talks about the wicked ways of anthrax and the even deadlier potential scourge of smallpox... |
BusinessWeek
August 4, 2003
Gene G. Marcial |
A Radiation Antidote? Tiny Hollis-Eden Pharmaceuticals is red-hot: Its shares zoomed from 3.39 last October to 16.97 on July 9, before easing to 16.09 on July 23. What's firing things up? Some pros are turned on by prospects of its "immune-regulating hormones" in treating immune-system disorders -- including radiation woes. |
Pharmaceutical Executive
December 1, 2005
Anthony Tao |
The Avian Few: Is it Too Late for Pharma to Re-enter the Vaccine Fray? Small profit margins and high litigation risks drove most companies out of the vaccine business decades ago. As a possible pandemic looms, pharma re-enters the fray. Is it too late? |
The Motley Fool
December 3, 2009 |
Behind the Business: 3 Questions for Vical Biotech company Vical provides key insights for shareholders and potential investors. |
Pharmaceutical Executive
December 1, 2010
Walter Armstrong |
Vaccines: Progress in Preventing Bad Bugs Long on the sidelines of pharma R&D, vaccine development is moving to center stage as most of the big pharmas diversify, spreading their risk among the full gamut of revenue sources. |
Chemistry World
August 20, 2014
Maria Burke |
Doctors turn to experimental Ebola treatments The emergency use of an experimental medicine is highly unusual, but the WHO has declared the Ebola outbreak a public health emergency of international concern. |
National Defense
March 2005
Sandra I. Erwin |
Pentagon Redirects Priorities In Chemical-Biological Defense The Pentagon will broaden the scope of its chemical and biological defense programs, in an effort to prepare for future domestic emergencies, officials say. |
Fast Company
Sarah Kessler |
Why There Is No Available Ebola Vaccine Ebola has the unprofitable qualities of being both relatively rare and infecting a mostly poor population. No pharma company wanted to foot the bill for human trials and production. |
Inc.
May 1, 2002
Kenneth Klee |
The Industry You Can't Afford to Miss After more than two decades of hype, hope, disappointment, and progress, the hundreds of mostly small, money-burning companies that make up the biotech industry are experiencing a decisive shift in their relationship with the giant, rich pharmaceutical companies... |
The Motley Fool
July 15, 2011
Brian Orelli |
Vical Transplants Some Firepower A licensing deal with Astellas gives the company a shot in the arm. |
Chemistry World
July 24, 2009
Matt Wilkinson |
Pharma's shot in the arm? As swine flu cases continue to erupt around the globe, the latest financial results from pharmaceutical companies Roche and GlaxoSmithKline reveal that sales of their antiviral drugs have soared. |
The Motley Fool
May 22, 2007
Mike Havrilla |
An Emergent Opportunity The vaccine developer guided for revenue growth of 10% to 15% for this year. Emergent also has a strong balance sheet, with more than $67 million in cash and investments. Investors, take note. |
Mother Jones
Jan/Feb 2002
Bill Hogan |
A Biodefense Boondoggle As pharmaceutical companies line up for multimillion-dollar contracts to make bioterrorism vaccines, some question whether the industry is up to the job... |
Chemistry World
December 3, 2014
Maria Burke |
Ebola vaccine passes first safety hurdle The vaccine was developed collaboratively by scientists at the NIH's National Institute of Allergy and Infectious Diseases, and at Okairos, a biotechnology company acquired by GlaxoSmithKline. |
